Summit Therapeutics

Recent news

• A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $43
  Market Newswire · 2026/9/30
• Rating change
  Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Raises Target Price to $9.8
  Market Newswire · 2026/6/22
• Rating change
  Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
  Market Newswire · 2026/6/1
• Rating change
  Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30
  Market Newswire · 2026/8/27
• Rating change
  Wolfe Research Initiates Summit Therapeutics(SMMT.US) With Hold Rating
  Market Newswire · 2026/8/17
• Rating change
  A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $40
  Market Newswire · 2026/7/24
• Rating change
  Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $38
  Market Newswire · 2026/7/29
• H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Hold Rating
  Market Newswire · 2026/9/23
• Rating change
  Jefferies Upgrades Summit Therapeutics(SMMT.US) to Buy Rating, Raises Target Price to $25
  Market Newswire · 2026/9/9
• Rating change
  UBS Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $33
  Market Newswire · 2026/9/14
• Rating change
  Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/9/14
• Rating change
  Clear Street Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $31
  Market Newswire · 2026/9/3
• Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20
  Market Newswire · 2026/10/1
• Rating change
  TD Cowen Maintains Summit Therapeutics(SMMT.US) With Buy Rating
  Market Newswire · 2026/7/28
• Rating change
  Guggenheim Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/6/1
• Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18
  Market Newswire · 2026/9/21
• Rating change
  A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $15 to $40
  Market Newswire · 2026/7/25
• Rating change
  Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Maintains Target Price $9.8
  Market Newswire · 2026/8/11
• Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41
  Market Newswire · 2026/9/14

Headlines are aggregated automatically and are not independently verified or edited by our team.